Back to top

BeOne Medicines Targets Esophageal Cancer With New Tislelizumab Trial in Japan

BeOne Medicines ($ONC) announced an update on their ongoing clinical study. BeOne Medicines (ONC) is launching a Phase 2 study in Japan to test dif...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

BeOne Medicines Ltd. - Sponsored ADR (ONC)